Abstract: Methods for preventing or treating subjects having cancer based on the identification of pharmaceutical agents that target cancer stem cells (CSCs) have been identified. These methods include administering to the subject an effective amount of a COX2 inhibitor and an effective amount of a YAP1 inhibitor. In addition, methods of enhancing chemotherapeutic responses in cancer patients have been discovered and are described herein.
Type:
Grant
Filed:
March 7, 2017
Date of Patent:
January 12, 2021
Assignee:
The Johns Hopkins University
Inventors:
Mohammad O. Hoque, David Sidransky, Akira Oki
Abstract: The present invention relates to highly stable drug dosage forms comprising. The invention also contemplates said highly stable drug dosage forms for the treatment of diseases where inhibition of 4-hydroxyphenylpyruvate dioxygenase 5 will result at improving the health of the patient.
Type:
Grant
Filed:
February 9, 2017
Date of Patent:
January 12, 2021
Assignee:
DIPHARMA S.A.
Inventors:
Chiara Conti, Salvatore Agostino Giammillari, Giuseppe Maccari
Abstract: A method of identifying cancer stem cell markers in a human primary tumor is disclosed. The method comprises: (a) in vivo passaging the primary tumor; and (b) comparing a level of at least one antigen in a first population of passaged tumor cells of the primary tumor with a second population of tumor cells of the primary tumor, wherein an increase in the amount of the antigen in the first population of tumor cells as compared to the amount of the antigen in the second population of tumor cells is indicative of a cancer stem cell marker in the human primary tumor.
Type:
Grant
Filed:
June 25, 2015
Date of Patent:
January 5, 2021
Assignee:
Tel HaShomer Medical Research Infrastructure and Services Ltd.
Abstract: Provided are compositions comprising beta-alanylhistidine peptides and/or beta-alanines, and methods for administering these peptides and amino acids. In one aspect, the compositions and methods cause an increase in the blood plasma concentrations of beta-alanine and/or creatine.
Type:
Grant
Filed:
February 27, 2018
Date of Patent:
January 5, 2021
Assignee:
Natural Alternatives International, Inc.
Abstract: The present disclosure provides methods and compositions for testosterone replacement therapy. The methods and compositions employ a fixed dose dosing regimen that does not require titration or dose adjustments and that can provide a therapeutically effective amount of a testosterone ester while avoiding unacceptably high testosterone levels.
Type:
Grant
Filed:
December 26, 2019
Date of Patent:
January 5, 2021
Inventors:
Nachiappan Chidambaram, Satish Kumar Nachaegari, Mahesh V. Patel, Kilyoung Kim
Abstract: The invention relates to methods of inhibiting side effects associated with vaccination in a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject before the subject is vaccinated, wherein the pharmaceutical composition comprises: a) a non-steroidal anti-inflammatory drug (NSAID); and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine and cetirizine and combinations thereof.
Abstract: A method for reducing macrophage migration inhibitory factor (MIF or MMIF) cytokine or its biological activity, including the step of administering an isothiocyanate functional surfactant to a patient having a disease or condition wherein MIF cytokine or its biological activity is implicated in the disease or condition.
Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
Abstract: The present disclosure targets the Zika virus and other disease-causing microbes including viruses, bacteria, fungi, and parasites. It does this using agents and methods with little toxicity compared to existing therapies.
Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
Abstract: A method for treating benign prostatic hyperplasia (BPH), prostatitis, and/or prostate cancer, including the step of administering an isothiocyanate functional surfactant to a patient affected by benign prostatic hyperplasia, prostatitis, and/or prostate cancer.
Abstract: Nitro oleic acid and related metabolites are agonists of PPAR-?. Surprisingly, nitro oleic acid is a more potent agonist of PPAR-?, relative to nitro linoleic acid. Thus, nitro oleic acid and its metabolites, as well as their pharmaceutically acceptable salts and prodrug forms, are candidate therapeutics for the treatment of type-2 diabetes, which results from insulin resistance accompanying the improper functioning of PPAR-?.
Type:
Grant
Filed:
January 21, 2020
Date of Patent:
December 22, 2020
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Education
Inventors:
Bruce A. Freeman, Francisco J. Schopfer
Abstract: A method for treating skin cancer including the steps of applying an isothiocyanate functional surfactant to an area affected by skin cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.
Abstract: The invention provides a composition comprising methylphosphonic acid or a salt thereof for human consumption. The invention also provides a method for treating aging and/or improving health in a human. Methods of the invention involve providing or administering methylphosphonic acid or a salt thereof to a human in need thereof for consumption. The invention provides nutritional and pharmaceutical compositions and articles containing such compositions including, for example, a nutritional supplement, a beverage, a food substance, a prepackaged food or meal, or a nutraceutical, as well as a pharmaceutical.
Abstract: The invention features dosing regimens and pharmaceutical formulations for oral administration of palovarotene. The dosing regimens can reduce heterotopic ossification, reduce the number of flare-ups, and/or reduce the severity of flare-ups in subjects suffering from fibrodysplasia ossificans progressiva.
Type:
Grant
Filed:
June 8, 2017
Date of Patent:
December 15, 2020
Assignee:
Clementia Pharmaceuticals Inc.
Inventors:
Clarissa Desjardins, Donna Roy Grogan, Jeffrey Neal Packman, Mark Harnett
Abstract: Provided are: a composition containing 96-99 area % of eicosapentaenoic acid alkyl ester, the composition having an arachidonic acid alkyl ester content of 0.7 area % or less, and an eicosapentaenoic-acid-alkyl-ester mono-trans isomer content of 2.5 area % or less; and a method for producing a composition containing a high concentration of eicosapentaenoic acid alkyl ester, the method including performing precision distillation on a composition containing eicosapentaenoic acid alkyl ester, obtained by alkyl esterification of a raw material oil containing eicosapentaenoic acid, under a vacuum of 0.2 Torr or lower and a temperature of 190° C. or lower in the entire column, and performing a concentration treatment on the precision-distilled composition using chromatography.
Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
Type:
Grant
Filed:
December 5, 2019
Date of Patent:
December 15, 2020
Assignee:
Celgene Quanticel Research, Inc.
Inventors:
Young K. Chen, Toufike Kanouni, Jeffrey Alan Stafford, James Marvin Veal
Abstract: A method for treating an infectious disease, including the step of administering an isothiocyanate functional surfactant to a patient having an infectious disease.
Abstract: It relates to an oil-in-water nanoemulsion composition having a continuous aqueous phase and dispersed oil droplets, wherein the nanoemulsion comprises: (a) clobetasol; (b) one or more oil components; and (c) one or more surfactants; together with one or more pharmaceutically acceptable excipients or carriers wherein: the osmolality of the nanoemulsion is comprised from 100 mOsm/Kg to 500 mOsm/Kg; the droplet average size measured by Dynamic light scattering is comprised from 1 nm to 500 nm; the weight ratio between the oil components and the sum of the oil components and one or more surfactants is comprised from 0.001 to 0.5; the weight ratio between the oil component and clobetasol is comprised from 1:1 to 200:1; and the weight ratio between the surfactant and clobetasol is comprised from 2:1 to 200:1. It also relates to processes for its preparation, its use as a medicament, and in the prophylaxis and/or treatment of inflammatory diseases or conditions.
Type:
Grant
Filed:
January 18, 2018
Date of Patent:
December 8, 2020
Assignee:
LABORATORIOS SALVAT, S.A.
Inventors:
Javier Sanagustin Aquilue, María Del Carmen Lendínez Gris, Maria Isabel Delgado Gañán